ATE555782T1 - Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz - Google Patents

Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz

Info

Publication number
ATE555782T1
ATE555782T1 AT03744567T AT03744567T ATE555782T1 AT E555782 T1 ATE555782 T1 AT E555782T1 AT 03744567 T AT03744567 T AT 03744567T AT 03744567 T AT03744567 T AT 03744567T AT E555782 T1 ATE555782 T1 AT E555782T1
Authority
AT
Austria
Prior art keywords
patient
prevention
treatment
heart failure
cardiovascular diseases
Prior art date
Application number
AT03744567T
Other languages
English (en)
Inventor
Garth James Smith Cooper
John Richard Baker
Original Assignee
Philera New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philera New Zealand Ltd filed Critical Philera New Zealand Ltd
Application granted granted Critical
Publication of ATE555782T1 publication Critical patent/ATE555782T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT03744567T 2002-03-08 2003-03-10 Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz ATE555782T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ51772102 2002-03-08
NZ51772502 2002-03-11
US36438202P 2002-03-12 2002-03-12
PCT/NZ2003/000042 WO2003077901A1 (en) 2002-03-08 2003-03-10 Preventing and/or treating cardiovascular disease and/or associated heart failure

Publications (1)

Publication Number Publication Date
ATE555782T1 true ATE555782T1 (de) 2012-05-15

Family

ID=28046135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744567T ATE555782T1 (de) 2002-03-08 2003-03-10 Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz

Country Status (10)

Country Link
US (4) US6951890B2 (de)
EP (2) EP1487431B1 (de)
JP (1) JP4860906B2 (de)
CN (1) CN1649577A (de)
AT (1) ATE555782T1 (de)
AU (1) AU2003225442B2 (de)
CA (1) CA2478997C (de)
DK (2) DK2500018T3 (de)
ES (1) ES2386782T3 (de)
WO (1) WO2003077901A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
JP2005504060A (ja) * 2001-08-24 2005-02-10 メイン・メデイカル・センター・リサーチ・インステイテユート 銅依存性の非伝統的前炎症性サイトカイン輸送およびそれに関連する方法、組成物およびキット
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
ATE555782T1 (de) 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
EP1531827A4 (de) * 2002-05-24 2009-07-08 Univ Michigan Kupfer-verringernde behandlung für entzündliche und fibrotische erkrankungen
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
EP2236131A3 (de) 2003-07-01 2011-03-02 President and Fellows of Harvard College SIRT1 Modulatoren zur Veränderung der Lebensdauer/Stressreaktion von Zellen/Organismen
AU2004298393A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7563460B2 (en) * 2004-02-26 2009-07-21 Med Five, Inc. Enteric coated oral pharmaceutical to erode kidney stones
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
ES2449066T3 (es) 2004-07-19 2014-03-18 Philera New Zealand Limited Síntesis de trietilentetraminas
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
WO2006104398A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
WO2006104402A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
AU2006235123A1 (en) * 2005-04-07 2006-10-19 Astrum Therapeutics Pty. Ltd. Complementary compositions to reduce blood glucose levels and treat diabetes
US20110136157A1 (en) * 2005-04-25 2011-06-09 Garth James Smith Cooper Copper regulation evaluation and therapy
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CA2632697C (en) * 2005-11-09 2016-01-05 Protemix Corporation Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
WO2007084818A2 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
KR100821649B1 (ko) * 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
AU2007217500A1 (en) * 2006-02-21 2007-08-30 Astrum Therapeutics Pty. Ltd. Compositions to reduce blood glucose levels and treat diabetes
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
EP2026833A4 (de) * 2006-06-01 2012-05-30 Univ Vermont Verfahren zur herz-pai-1-hemmung
KR100816798B1 (ko) * 2006-09-08 2008-03-25 (주)팜스웰 의약용 트리에틸렌테트라민 이염산염의 제조방법
WO2008111956A2 (en) * 2007-03-09 2008-09-18 Symcopeia Company Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
US20100311092A1 (en) * 2007-11-30 2010-12-09 Kurland Irwin J Metabolic fuel switching biomarker
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
US20100234906A1 (en) * 2009-03-16 2010-09-16 Pacesetter, Inc. System and method for controlling rate-adaptive pacing based on a cardiac force-frequency relation detected by an implantable medical device
JP5896375B2 (ja) 2011-09-09 2016-03-30 池田食研株式会社 改変型グルコース脱水素酵素遺伝子
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CZ307108B6 (cs) * 2013-09-06 2018-01-17 Vysoké Učení Technické V Brně Multifunkční poloprovozní jednotka pro snižování polutantů z odpadního plynu
EP2845640B1 (de) 2013-09-06 2018-10-24 Vysoké Ucení Technické V Brne Multifunktion-Verfahrenseinheit zur Reduzierung der Schadstoffkonzentration in einem Abgas
WO2016110701A1 (en) * 2015-01-07 2016-07-14 Nottingham University Hospitals Nhs Trust Biomarkers related to kidney function and methods involving their use
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
US11865162B2 (en) 2016-07-01 2024-01-09 Marshall University Research Corporation Compositions and methods for treatment of uremic cardiomyopathy
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
DK3652145T3 (da) 2018-05-04 2025-10-20 Orphalan S A Krystallinsk form af triethylentetramintetrahydrochlorid og farmaceutisk anvendelse deraf
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20200319196A1 (en) * 2019-04-02 2020-10-08 The Regents Of The University Of Michigan Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease
EP3982943A4 (de) * 2019-06-17 2023-07-05 Philera New Zealand Ltd. Kombinierte behandlungen für störungen des zentralen nervensystems
CN112138024A (zh) * 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
CN110464717B (zh) * 2019-09-23 2022-02-18 张建国 一种2,4-二羟基苯甲酸在制备降低血糖的药物的应用
GB2612210B (en) * 2020-06-24 2025-08-27 Reverspah Llc Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine
CN115998955B (zh) * 2022-12-09 2024-12-20 首都医科大学附属北京安贞医院 一种静脉桥的醛铬复合交联方法
KR102878403B1 (ko) * 2023-01-25 2025-10-28 김성국 동맥경화 치료용 킬레이션 약학 조성물 및 체외 역박동기를 이용한 동맥경화 치료용 킬레이션 약학 조성물의 투여방법

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791988A (en) 1972-03-23 1974-02-12 Hoffmann La Roche Diagnostic test for glucose
PL105793B1 (pl) 1977-11-24 1979-10-31 Sposob otrzymywania soli kwasow dwukarboksylowych i poliamin
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4323558A (en) 1979-09-10 1982-04-06 Nelson Research & Development Co. Topical trien containing pharmaceutical compositions and methods of use
US4371374A (en) 1980-11-17 1983-02-01 The Rockefeller University Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine
JPS57144215A (en) 1981-03-02 1982-09-06 Nippon Nousan Kogyo Kk Composition for improving lipometabolism
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
HU207452B (en) 1986-03-21 1993-04-28 Eurasiam Lab Method for producing therapeutical preparations containing active ingredient having biologicallu active protein structure
CH666814A5 (it) 1986-07-24 1988-08-31 Inpharzam Int Sa Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
CH667590A5 (it) 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .
US4866090A (en) 1988-01-07 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
EP0331014A3 (de) 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
JPH01294631A (ja) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
ES2106318T3 (es) 1991-12-06 1997-11-01 North Shore Univ Hospital Metodo para reducir las infecciones relacionadas con dispositivos medicos.
US5246970A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
JP3157622B2 (ja) 1992-06-05 2001-04-16 株式会社ミツカングループ本社 フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JPH06298738A (ja) * 1993-04-15 1994-10-25 Yamanouchi Pharmaceut Co Ltd ５−アミノピラゾール誘導体
JPH07118148A (ja) 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
AU1447095A (en) 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US5854271A (en) 1994-05-02 1998-12-29 Cytos Pharmaceuticals, L.L.C. Effective method for the amelioration and prevention of tissue and cellular damage
WO1996012483A1 (en) 1994-10-25 1996-05-02 Washington University Method of inhibiting nitric oxide formation
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP3988838B2 (ja) * 1996-05-29 2007-10-10 日本製粉株式会社 化粧料
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
JP2001514661A (ja) 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
JPH10324629A (ja) * 1997-03-28 1998-12-08 Otsuka Pharmaceut Co Ltd Ａｇｅ生成阻害組成物
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6576672B1 (en) 1998-08-21 2003-06-10 Michael A. Murphy Polyamine treatment of neurological disorders
US20050085555A1 (en) 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US5972985A (en) 1997-11-03 1999-10-26 Cytos Pharmaceuticals, Llc Histidine containing nutriceutical compositions
WO1999039712A1 (en) 1998-02-04 1999-08-12 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
WO2000018891A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase assay: methods and materials
JP2000204037A (ja) 1999-01-12 2000-07-25 Tsumura & Co 筋萎縮性側索硬化症治療薬
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
US20030050434A1 (en) 1999-06-18 2003-03-13 Cooper Garth J.S. Peptide
US20030166561A1 (en) 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
CA2375207A1 (en) 1999-06-18 2000-12-28 Garth James Smith Cooper Peptide having preptin functionality
ATE367430T1 (de) 2000-05-11 2007-08-15 Procter & Gamble Hochkonzentrierte wäscheweichspülerzusammensetzungen und diese enthaltende mittel
CA2429982C (en) 2000-12-01 2010-07-13 Ning Li Copper chelators for treating ocular inflammation
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
EP1373893A2 (de) 2001-03-30 2004-01-02 Protemix Corporation Limited Phosphoproteinziel für insulin und seine antagonisten
WO2003002732A1 (en) 2001-06-27 2003-01-09 Biovitrum Ab Citrate lyase poly peptides
AU2002354951A1 (en) 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
CN1617737A (zh) 2001-11-26 2005-05-18 普罗特米克斯公司 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
US20040038861A1 (en) 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US7144706B2 (en) 2002-01-03 2006-12-05 Duke University Methods of modulating localization and physiological function of IP3 receptors
NZ534699A (en) 2002-01-18 2008-12-24 Protemix Corp Ltd Glycoisoforms of adiponectin and uses thereof
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
CA2473102A1 (en) 2002-01-29 2003-07-29 Protemix Corporation Limited Suppression of cytotoxic protein conformers
WO2003074559A1 (en) 2002-03-01 2003-09-12 Protemix Corporation Limited Falp proteins
ATE555782T1 (de) 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
WO2003075910A1 (en) * 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2003082259A1 (en) 2002-04-03 2003-10-09 Puleva Biotech, S.A. Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
WO2003093311A1 (en) 2002-04-29 2003-11-13 Protemix Corporation Limited Proteins with deglycating activities and methods of using same
EP1531827A4 (de) 2002-05-24 2009-07-08 Univ Michigan Kupfer-verringernde behandlung für entzündliche und fibrotische erkrankungen
JP2003343552A (ja) * 2002-05-27 2003-12-03 Koyo Seiko Co Ltd 円錐ころ軸受
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
EP1539131A4 (de) 2002-07-23 2009-07-08 Univ Michigan Tetrapropylammoniumtetrathiomolybdat und verwandte verbindungen für anti-angiogene therapien
AU2003258895A1 (en) 2002-08-01 2004-02-23 Protemix Discovery Limited Methods of use of compounds with preptin function
US20060116318A1 (en) 2002-08-01 2006-06-01 Jillian Cornish Preptin methods of use
US20040142393A1 (en) 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
WO2004017957A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
AU2003285686A1 (en) 2002-12-23 2004-07-14 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2517755A1 (en) 2003-03-21 2004-09-30 Palumed Sa Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
CN1791408A (zh) 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
JP2006528690A (ja) 2003-05-07 2006-12-21 ディーエムアイ バイオサイエンシズ インコーポレイテッド 口腔ケア方法および製品
US7176239B2 (en) 2003-07-11 2007-02-13 Suming Wang Methods and compositions for treatment of Ataxia-telangeictasia
EP1687330A4 (de) 2003-10-28 2007-03-14 Protemix Discovery Ltd Peptide mit antiobesitaswirkung und andere verwandte anwendungen
AU2004298393A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
ES2449066T3 (es) 2004-07-19 2014-03-18 Philera New Zealand Limited Síntesis de trietilentetraminas
WO2006068516A1 (en) 2004-12-20 2006-06-29 Protemix Corporation Limited Implantable medical devices coated with or containing copper chelating compounds

Also Published As

Publication number Publication date
CA2478997A1 (en) 2003-09-25
EP1487431A1 (de) 2004-12-22
DK2500018T3 (en) 2017-10-02
AU2003225442B2 (en) 2010-02-04
US20060009534A1 (en) 2006-01-12
DK1487431T3 (da) 2012-08-20
JP4860906B2 (ja) 2012-01-25
US20030203973A1 (en) 2003-10-30
US8034799B2 (en) 2011-10-11
US8987244B2 (en) 2015-03-24
CA2478997C (en) 2013-12-17
US6951890B2 (en) 2005-10-04
ES2386782T3 (es) 2012-08-30
US20110212188A1 (en) 2011-09-01
JP2005533003A (ja) 2005-11-04
EP2500018A1 (de) 2012-09-19
US20140113969A1 (en) 2014-04-24
EP1487431A4 (de) 2006-10-25
US8563538B2 (en) 2013-10-22
EP2500018B1 (de) 2017-07-19
CN1649577A (zh) 2005-08-03
WO2003077901A1 (en) 2003-09-25
HK1071313A1 (en) 2005-07-15
AU2003225442A1 (en) 2003-09-29
EP1487431B1 (de) 2012-05-02

Similar Documents

Publication Publication Date Title
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
BR9710682A (pt) Composi-{es e m-todos para tratar ou prevenir doen-as das vias do organismo
CO5611156A2 (es) Metodos de tratamiento de enfermedad vascular
PT955880E (pt) Metodo e aparelho para tratamento de arritmias cardiacas sem alvo discreto
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
NO993393D0 (no) Fotokjemoterapeutiske blandinger
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
WO2004101024A3 (en) Method for treating glandular diseases and malignancies
ATE424824T1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
EP1588736A3 (de) Kombinierte elektrische Stimulation und Mikroperfusion
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
EA199900724A1 (ru) Способы лечения, профилактики и защиты кровеносных сосудов от повреждений (варианты), способы лечения и профилактики различных видов гипертензии, атеросклероза (варианты)
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
ATE419037T1 (de) Verwendung eines mittel zur therapie der herzhypertrophie
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
RU93015924A (ru) Способ лечения трофических язв нижних конечностей
WO2004037120A3 (en) Implantable medical devices using zinc
RU2002115574A (ru) Способ лечения эпидидимоорхита
TW200602067A (en) Removal agent of circulating dysfunction factor
RU93045689A (ru) Способ лечения хронической артериальной недостаточности конечностей
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита